



OPEN

Analysis of immune related gene expression profiles and immune cell components in patients with Barrett esophagus

Lin Shi, Renwei Guo, Zhuo Chen, Ruonan Jiao, Shuangshuang Zhang & Xuanxuan Xiong✉

Barrett's esophagus (BE) is a well-known precancerous condition of esophageal adenocarcinoma. However, the immune cells and immune related genes involved in BE development and progression are not fully understood. Therefore, our study attempted to investigate the roles of immune cells and immune related genes in BE patients. The raw gene expression data were downloaded from the GEO database. The limma package in R was used to screen differentially expressed genes (DEGs). Then we performed the least absolute shrinkage and selection operator (LASSO) and random forest (RF) analyses to screen key genes. The proportion of infiltrated immune cells was evaluated using the CIBERSORT algorithm between BE and normal esophagus (NE) samples. The spearman index was used to show the correlations of immune genes and immune cells. Receiver operating characteristic (ROC) curves were used to assess the diagnostic value of key genes in BE. A total of 103 differentially expressed immune-related genes were identified between BE samples and normal samples. Then, 7 genes (CD1A, LTF, FABP4, PGC, TCF7L2, INSR, SEMA3C) were obtained after Lasso analysis and RF modeling. CIBERSORT analysis revealed that resting CD4 T memory cells and gamma delta T cells were present at significantly lower levels in BE samples. Moreover, plasma cell and regulatory T cells were present at significantly higher levels in BE samples than in NE samples. INSR had the highest AUC values in ROC analysis. We identified 7 immune related genes and 4 different immune cells in our study, that may play vital roles in the occurrence and development of BE. Our findings improve the understanding of the molecular mechanisms of BE.

Barrett's esophagus (BE) is a well-documented precancerous condition of esophageal adenocarcinoma (EAC)¹, which is characterized by the occurrence of metaplasia and is followed by cellular changes in the columnar epithelium² due to many causes, such as gastroesophageal reflux disease (GERD)³. It is difficult to define an accurate global prevalence of BE. However, recent studies have shown that nearly 15% of GERD patients suffer from BE worldwide and the incidence of BE is higher in patients with heartburn². A multinational systematic review of 28 studies reported that the prevalence of GERD in adult populations had increased by approximately 50% in 20 years⁴. As a common complication of GERD, the incidence of BE is rapidly increasing³. Therefore, it can be confirmed that the overall prevalence of BE is increasing⁵. However, the molecular mechanism of BE is still unclear.

The local immune system in esophageal mucous plays a vital role in BE development and progression^{6,7}. Fork head box protein P3 (FOXP3) is always a marker of CD4+ regulatory T cells, which suppress local immunity, aid in tumor cell immune escape and promote tumor development and progression⁸. Previous studies showed that BE tissues always had significantly higher FOXP3 expression than normal tissues⁹. Moreover, FOXP3+ T cells were more common in BE tissues¹⁰. In addition, study also shown that RALDH2, an anti-inflammatory gene, was associated with the expression of myeloid dendritic cells and had a higher expression in BE tissues⁹.

Although immune cells have been evaluated in many studies, the impact of immune cells and immune related genes in BE development and progression has not been fully investigated. Fortunately, bioinformatics analysis generates large and complex biological data, and these biological data can help us study the molecular mechanisms of different diseases^{11,12}. Therefore, our present study aims to analyze immune-related gene expression profiles and immune infiltration in BE patients with bioinformatic methods. Our study will provide new insights into the pathogenesis of BE and may help develop immunotherapies for BE patients.

Department of Gastroenterology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. ✉email: xhxx0117@gmail.com

Materials and methods

Data collection. The transcription profile dataset of Barrett's Esophagus was obtained from the NCBI GEO databases (<http://www.ncbi.nlm.nih.gov/geo/>). The accession number is GSE39491¹³, which is based on the GPL571 Platform. The dataset contains 80 fresh frozen tissue samples of Barrett's metaplasia (40 samples) and matched normal esophagus (NE, 40 samples) from squamous esophagus. The background correction, normalization and probe summarization of the microarray dataset with raw data were carried out by R software. The 2498 immune-related genes were downloaded from the ImmPort database (Immunology Database and Analysis Portal database, <https://www.immport.org/shared/home>).

Differentially expressed immune-related gene identification. The Linear Models for Microarray Data (limma) package in Bioconductor was used to identify differentially expressed genes (DEGs) by comparing expression values between Barrett's metaplasia and normal mucosa. Genes with cutoff criteria of $|\log_2FC$ (fold change) >1 and adjusted p value <0.05 were selected as the threshold for DEGs. We used Benjamini–Hochberg procedure, also known as FDR method, to adjust the p value^{14,15}. A volcano plot and a heatmap were used to display these genes. Then, the DEGs were overlapped with the 2498 immune-related genes, resulting in 103 immune-related DEGs.

GO and KEGG enrichment analyses of DEGs. Using the clusterProfiler R package from Bioconductor, we performed Gene Ontology analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to identify the biological processes for 103 immune-related genes^{16–18}. $P < 0.05$ was considered as the cut-off criterion.

Identification of key genes by lasso and random forest analysis. By constructing a penalty function for all variables, Lasso can compress unimportant variable coefficients to 0, thus excluding those variables, and then the independent variables that have a greater impact on the outcome are selected in the final analysis. The 103 immune-related genes were entered into the Lasso regression analysis to screen key genes by the glmnet package in R. We also constructed a random forest model (RF) to screen key genes by the randomForest package in R^{19,20}. RF is an algorithm that performs classification or regression by combining the voting results of multiple decision trees. The number of decision trees constructed in this study was 500. The RF selected or excluded variables according to the feature importance. An RF model was used to predict the BE status in each sample based on gene expression profiles. Mean decrease accuracy is an important indicator of variable importance, which directly measures the effect of each variable²¹. Therefore, mean decrease accuracy was used to identify core genes. In our study, we refer to some previous studies that the results of mean decrease gini were similar to mean decrease accuracy²². Therefore we also show mean decrease gini at the same time. The top 20 genes with mean decreased accuracy were selected as key genes by the RF model^{19,22}. The overlapping genes after LASSO and RF analyses were used as the key genes.

Analysis of immune cell infiltration. Using its deconvolution algorithm, CIBERSORT can quantify the abundance levels of 22 immune cell subtypes based on the expression files^{23,24}. To compare the difference between BE samples and NE samples in immune cells, the CIBERSORT package was used in R software. Samples with $P < 0.05$ in the CIBERSORT analysis results were used in further analysis. The Mann–Whitney U test was used to compare differences in immune cell subtypes, and violin plots were generated for the BE samples and NE samples.

Statistical analysis. The Wilcoxon test was used to compare the proportions of 22 immune cells based on CIBERSORT analysis between BE samples and NE samples. ROC curves were used to evaluate the diagnostic value of each core gene and were constructed by Stata 14.0. $P < 0.05$ was considered statistically significant.

Results

Identification of DEGs and immune related DEGs. After data preprocessing, 1121 DEGs were screened between BE and NE samples, including 480 upregulated genes and 647 downregulated genes (Supplementary table 1). The distribution and expression of DEGs are shown by volcano plot and heatmap plot (Fig. 1). The 2498 immune-related genes overlapped with 1121 DEGs, obtaining 103 immune related genes. A volcano plot and a heatmap plot of overlapping immune-related genes are also shown (Fig. 2A,B, Supplementary table 2).

Enrichment analysis for immune-related DEGs. GO and KEGG analyses were performed to further explore the mechanisms of immune-related DEGs. The top 5 GO terms were receptor ligand activity, leukocyte migration, cell chemotaxis, response to lipopolysaccharide and response to molecules of bacterial origin (Fig. 3A). In addition, the KEGG items were associated with cytokine–cytokine receptor interaction, MAPK signaling pathway, IL–17 signaling pathway, fluid shear stress and atherosclerosis and lipid and atherosclerosis (Fig. 3B).

Identification of key immune-related DEGs by LASSO analysis. To further identify key immune-related genes, LASSO analysis was performed for the 103 immune-related DEGs. Eleven candidate key genes were identified by LASSO analysis: CD1A, CXCL14, LTF, FABP4, PGC, MUC4, TCF7L2, SEMA3C, IL1R2, INSR, and IL12A, which were considered candidate optimal immune related biomarkers (Fig. 4A,B). In addition, the RF for the 103 immune-related DEGs was also used to screen gene signatures, and the top 20 gene




Figure 1. Identification of DEGs from GEO dataset. (A) The volcano plot of DEGs between BE and NE samples. (B) The heatmap plot of DEGs between BE and NE samples.





Figure 2. Identification of DEGs from GEO dataset. (A) The volcano plot of immune related DEGs between BE and NE samples. (B) The heatmap plot of immune related DEGs between BE and NE samples.

signatures were retrieved (Fig. 4C, Supplementary table 3). Ultimately, there were 7 key overlapping genes after LASSO and RF analyses, CD1A, LTF, FABP4, PGC, TCF7L2, INSR, and SEMA3C, which were considered as the optimal immune-related biomarkers (Fig. 4D).

Immune cell analysis between BE and NE samples. The abundance levels of the 22 immune cells between BE samples and NE samples were further analyzed. The CIBERSORT algorithm indicated that plasma cells, CD8 + T cells, gamma delta T cells, and resting mast cells had a larger proportions in the BE and NE samples (Fig. 5A). A heatmap was drawn to show the proportions of immune cells in each sample (Fig. 5B). Figure 5C shows that resting CD4 T memory cells ($p=0.006$), and gamma delta T cells ($p<0.001$) were significantly lower in BE samples. In addition, plasma cells ($p=0.049$) and regulatory T cells ($p=0.029$) were significantly higher in BE samples than in NE samples. Differences in immune cells suggested the important role of the immune system in Barrett's esophagus.

Correlation analysis between key genes and immune cells. A Spearman correlation heatmap was drawn to show the relevance between key genes and immune cells among BE and NE samples. CD1A was only significantly associated with monocytes and resting dendritic cells in BE samples and NE samples, respectively. In BE samples, the LTF gene was associated with naïve B cells, resting NK cells and monocytes, while FABP4 was also associated with CD8 + T cells, and resting and activated dendritic cells. The PGC gene was associated with CD8 + T cells and resting dendritic cells. Moreover, INSR was significantly associated with CD8 + T cells.






Figure 4. Identification of the optimal immune-related biomarkers. (A,B) LASSO regression analysis. (C) Top 20 genes by RF model sort by accuracy. (D) Venn diagram of overlapping.




Figure 5. Distribution of immune cells between BE and NE samples. (A) Percentage of immune cells in each sample. (B) Heatmap. (C) Violin plot.

SEMA3C was significantly associated with CD8 + T cells, monocytes, plasma cells and neutrophils. Additionally, there were significant differences between T1DM and normal samples; the details are shown in the heatmap (Fig. 6A,B).

ROC analysis. ROC curves were performed to further explore the diagnostic accuracy of key genes respectively. Genes with an area under the ROC curve greater than 0.8 are shown in the article with INSR having the highest AUC values (Fig. 7).

Discussion

BE is a very common esophageal mucosal lesion worldwide. Immune cell components and immune related genes are vital in the BE and EAC microenvironments. In the present study, we identified 103 immune related DEGs between BE and NE samples based on genomic expression profile analysis. Then 11 candidate immune-related key biomarkers for BE were obtained by LASSO analysis, and the RF model was also used to screen potential key genes. Then, the 7 overlapping genes (CD1A, LTF, FABP4, PGC, TCF7L2, INSR, SEMA3C) from LASSO analysis and the RF model used to select the key genes. In addition, the CIBERSORT algorithm application indicated that CD4 T memory cells and gamma delta T cells were present at significantly lower levels in BE samples. Plasma cell and regulatory T cells were present at significantly higher levels in BE samples than in NE samples. Furthermore, we analyzed the correlation between key biomarkers and immune cells.

We first performed differential gene analysis by R software and obtained 1121 DEGs, Then 103 immune-related genes involved in BE were identified by intersecting 2498 immune-related genes with 1121 DEGs. Furthermore, enrichment analysis for immune related DEGs was conducted to explore gene functions. KEGG analysis indicated that cytokine—cytokine receptor interaction, MAPK signaling pathway, IL—17 signaling pathway, fluid shear stress and atherosclerosis and lipid and atherosclerosis were the top 5 significant pathways. The MAPK pathway is a well-known signaling pathway that is closely associated with the development and progression of various tumors^{25,26}. A previous study showed that RAS or BRAF mutations were detected in approximately 32% of all Barrett's adenocarcinomas, which indicated that disruption of the MAPK kinase pathway is a frequent but also early event in the development of Barrett's adenocarcinoma²⁷.

CD1a is a surface glycoprotein of 43–49 kDa that has been shown to be expressed by immune cells such as dendritic cells and Langerhans cells²⁸. Cappello et al. proposed that CD1a could be expressed in metaplastic epithelium of Barrett's esophagus, including gastric and intestinal types. However, normal gastrointestinal tissues do not express CD1a²⁸. In BE tissues, metaplastic epithelial cells expressing higher CD1a levels could help distinguish gastric-type Barrett's metaplasia from the presence of ectopic gastric epithelium in the esophageal mucosa²⁸. Moreover, epithelial CD1a + cells may interact with dendritic cells or T cells in the development of BE²⁸. Fatty acid binding protein 4 (FABP4), predominantly expressed in adipocytes and macrophages, is associated with the development and progression of various kinds of tumors²⁹. FABP4 may have a potential associations with hyperlipidemia, hyperinsulinemia, and insulin resistance, indirectly affecting cancer cells by influencing these factors³⁰. Multiple effects mediated by FABP4, such as insulin resistance, promote BE carcinogenesis³¹.

Lactotransferrin (LTF) is a member of the transferrin family that transfers iron to cells and controls the levels of free iron in the blood and external secretions. Some studies have reported that LTF is significantly lower in tumor tissues and that LTF may have a potential role in suppressing tumor growth and development^{32,33}. For patients with papillary thyroid carcinoma, macrophages, mast cells, natural killer (NK) cells, Tfh cells, activated dendritic cells (aDCs), B cells, Tregs, CD8 + T cells and DCs were associated with LTF expression, which indicated that LTF plays an important role in the tumor microenvironment³². Insulin receptor (INSR) is a proliferation regulator involved in aggressive behaviors in many types of cancer³⁴. In patients with BE, the insulin/insulin-like growth factor axis can mediate cancer progression and cause hyperinsulinemia and insulin resistance. The specific mechanisms involved in this tumor-promoting activity are unclear³¹. In gastric cancer, the high expression of INSR correlates with HER2 status and may have putative therapeutic implications³⁵. In addition, pepsinogen C (PGC) is expressed only in the mucosa of the gastric fundus and is expressed by all regions of the gastric mucosa. In a preliminary study, PGC was expressed by columnar non goblet cells in most areas without specialized intestinal metaplasia which can help clinicians identify high risk BE patients and guide endoscopic surveillance³⁶. Semaphorin 3C (SEMA3C) has been reported to drive a number of oncogenic programs, correlate poor cancer prognosis, and promote the progression of multiple different cancer types^{37,38}.

The transcription factor 7-like 2 (TCF7L2) gene has been identified as a novel transcription factor involved in epithelial-mesenchymal transition (EMT) in tumor cells³⁹. TCF7L2 is a member of the Wnt/b-catenin signaling pathway, which plays an important role in metabolism, cell differentiation/proliferation, and cell death³⁹. The Wnt – /β-catenin signaling pathway is responsible for cell growth, motility and differentiation during embryogenesis. The Wnt/b-catenin signaling pathway has been reported to be activated in the progression of BE⁴⁰. However the specific role of TCF7L2 in the development of BE is not fully understood. Previous studies have shown that TCF7L2 is closely associated with the development, progression and distant metastasis of various cancers such as pancreatic cancer⁴¹. The overexpressed TCF7L2 was associated with poor overall survival in patients with glioma⁴².

Finally, to explore the diagnostic accuracy of key genes, we performed ROC curve analysis and found a strong accuracy for the INSR (AUC = 0.93), which also provides a new biomarker for the diagnosis of BE.

Multiple analyses were performed to systematically investigate immune related genes, immune cells and their relationships in BE patients. Our study still has some limitations due to a lack of experimental validation and the use of a single dataset from the GEO. Future research needs to explore the detailed mechanism between the expression of distinct biomarkers and BE.




Figure 6. Spearman correlation of the key genes and the immune cells. (A) Correlation in BE samples. (B) Correlation in NE samples.




Figure 7. The ROC curve of each key genes.

Conclusions

In our present study, we identified 7 key genes, CD1A, LTF, FABP4, PGC, TCF7L2, INSR and SEMA3C as potential immune-related biomarkers in BE. Our study reveals the association between immune related genes and immune cells in BE patients for the first time. Our findings improve the understanding of the molecular mechanisms in BE and provide suggestions for novel therapy and diagnostic methods for BE patients.

Data availability

The raw data of this study are derived from the GEO data portal (<https://www.ncbi.nlm.nih.gov/geo/>), which are publicly available databases.

Received: 30 October 2021; Accepted: 23 May 2022

Published online: 02 June 2022

References

- Lin, P. H. *et al.* Risk prediction of Barrett's esophagus in a Taiwanese health examination center based on regression models. *Int. J. Environ. Res. Public Health* **18**, 1. <https://doi.org/10.3390/ijerph18105332> (2021).
- Fabian, T. & Leung, A. Epidemiology of Barrett's esophagus and esophageal carcinoma. *Surg. Clin. North Am.* **101**, 381–389. <https://doi.org/10.1016/j.suc.2021.03.001> (2021).
- Kuipers, E. J. & Spaander, M. C. Natural history of Barrett's esophagus. *Dig. Dis. Sci.* **63**, 1997–2004. <https://doi.org/10.1007/s10620-018-5161-x> (2018).
- El-Serag, H., Sweet, S., Winchester, C. & Dent, J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut* **63**, 871–880. <https://doi.org/10.1136/gutjnl-2012-304269> (2014).
- Zhang, C., Shen, Y., Wang, J., Zhou, M. & Chen, Y. Identification of key pathways and genes in Barrett's esophagus using integrated bioinformatics methods. *Mol. Med. Rep.* **17**, 3069–3077. <https://doi.org/10.3892/mmr.2017.8274> (2018).
- Gokon, Y. *et al.* Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression. *Virchows. Arch.* **477**, 825–834. <https://doi.org/10.1007/s00428-020-02854-0> (2020).
- Curtius, K., Wright, N. & Graham, T. An evolutionary perspective on field cancerization. *Nat. Rev. Cancer* **18**, 19–32. <https://doi.org/10.1038/nrc.2017.102> (2018).
- Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression—Implications for anticancer therapy. *Nat. Rev. Clin. Oncol.* **16**, 356–371. <https://doi.org/10.1038/s41571-019-0175-7> (2019).
- Lind, A. *et al.* The microenvironment in Barrett's Esophagus tissue is characterized by high FOXP3 and RALDH2 levels. *Front. Immunol.* **9**, 1375. <https://doi.org/10.3389/fimmu.2018.01375> (2018).
- Rubinkiewicz, M. *et al.* Foxp3+ lymphocyte count in Barrett's esophagus tissue is higher than in adjacent esophageal tissue. *Folia Med. Cracov.* **56**, 51–59 (2016).
- Lin, J., Lu, Y., Wang, B., Jiao, P. & Ma, J. Analysis of immune cell components and immune-related gene expression profiles in peripheral blood of patients with type 1 diabetes mellitus. *J. Transl. Med.* **19**, 319. <https://doi.org/10.1186/s12967-021-02991-3> (2021).
- Xu, W. H. *et al.* Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. *Aging (Albany NY)* **11**, 6999–7020. <https://doi.org/10.18632/aging.102233> (2019).
- Hyland, P. L. *et al.* Global changes in gene expression of Barrett's esophagus compared to normal squamous esophagus and gastric cardia tissues. *PLoS ONE* **9**, e93219. <https://doi.org/10.1371/journal.pone.0093219> (2014).
- Lai, P. M. R. & Du, R. Differentially expressed genes associated with the Estrogen receptor pathway in cerebral aneurysms. *World Neurosurg.* **126**, e557–e563. <https://doi.org/10.1016/j.wneu.2019.02.094> (2019).
- Hochberg, Y. & Benjamini, Y. More powerful procedures for multiple significance testing. *Stat Med* **9**, 811–818. <https://doi.org/10.1002/sim.4780090710> (1990).
- Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. *Prot. Sci. Publ. Prot. Soc.* **28**, 1947–1951. <https://doi.org/10.1002/pro.3715> (2019).
- Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG: Integrating viruses and cellular organisms. *Nucl. Acids Res.* **49**, D545–D551. <https://doi.org/10.1093/nar/gkaa970> (2021).
- Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucl. Acids Res.* **28**, 27–30. <https://doi.org/10.1093/nar/28.1.27> (2000).

19. Zhu, F. *et al.* Effect of immune cell infiltration on occurrence of pulmonary hypertension in pulmonary fibrosis patients based on gene expression profiles. *Front. Med. (Lausanne)* **8**(6717), 2021. <https://doi.org/10.3389/fmed.2021.671617> (2021).
20. He, J., Li, X. & Yu, M. Bioinformatics analysis identifies potential ferroptosis key genes in the pathogenesis of pulmonary fibrosis. *Front. Genet.* **12**, 788417. <https://doi.org/10.3389/fgene.2021.788417> (2021).
21. Wang, H., Yang, F. & Luo, Z. An experimental study of the intrinsic stability of random forest variable importance measures. *BMC Bioinf.* **17**, 60. <https://doi.org/10.1186/s12859-016-0900-5> (2016).
22. Wu, J. *et al.* Predicting in-hospital rupture of type A aortic dissection using Random Forest. *J. Thorac. Dis.* **11**, 4634–4646. <https://doi.org/10.21037/jtd.2019.10.82> (2019).
23. Felix Garza, Z. C. *et al.* Characterization of disease-specific cellular abundance profiles of chronic inflammatory skin conditions from deconvolution of biopsy samples. *BMC Med. Genom.* **12**, 121. <https://doi.org/10.1186/s12920-019-0567-7> (2019).
24. Newman, A. M. *et al.* Robust enumeration of cell subsets from tissue expression profiles. *Nat. Methods* **12**, 453–457. <https://doi.org/10.1038/nmeth.3337> (2015).
25. An, Y. *et al.* Clinicopathological and molecular characteristics of colorectal signet ring cell carcinoma: A review. *Pathol. Oncol. Res.: POR* **27**, 1609859. <https://doi.org/10.3389/pore.2021.1609859> (2021).
26. Lorenzo, C. & McCormick, F. SPRED proteins and their roles in signal transduction, development, and malignancy. *Genes Dev.* **34**, 1410–1421. <https://doi.org/10.1101/gad.341222.120> (2020).
27. Sommerer, F. *et al.* Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. *Oncogene* **23**, 554–558. <https://doi.org/10.1038/sj.onc.1207189> (2004).
28. Cappello, F., Rappa, F., Anzalone, R., La Rocca, G. & Zummo, G. CD1a expression by Barrett's metaplasia of gastric type may help to predict its evolution towards cancer. *Br. J. Cancer* **92**, 888–890. <https://doi.org/10.1038/sj.bjc.6602415> (2005).
29. Steen, K. A., Xu, H. & Bernlohr, D. A. FABP4/aP2 regulates macrophage redox signaling and inflammasome activation via control of UCP2. *Mol. Cell Biol.* **37**, 1. <https://doi.org/10.1128/MCB.00282-16> (2017).
30. Zhang, Y. *et al.* High expression of FABP4 and FABP6 in patients with colorectal cancer. *World J. Surg. Oncol.* **17**, 171. <https://doi.org/10.1186/s12957-019-1714-5> (2019).
31. Arcidiacono, D. *et al.* Hyperinsulinemia promotes esophageal cancer development in a surgically-induced duodeno-esophageal reflux murine model. *Int. J. Mol. Sci.* **19**, 1. <https://doi.org/10.3390/ijms19041198> (2018).
32. Qin, R., Li, C., Wang, X., Zhong, Z. & Sun, C. Identification and validation of an immune-related prognostic signature and key gene in papillary thyroid carcinoma. *Cancer Cell Int.* **21**, 378. <https://doi.org/10.1186/s12935-021-02066-9> (2021).
33. Jia, Y., Liu, Y., Han, Z. & Tian, R. Identification of potential gene signatures associated with osteosarcoma by integrated bioinformatics analysis. *PeerJ* **9**, e11496. <https://doi.org/10.7717/peerj.11496> (2021).
34. Chen, F. *et al.* Integrated analysis of cell cycle-related and immunity-related biomarker signatures to improve the prognosis prediction of lung adenocarcinoma. *Front. Oncol.* **11**, 666826. <https://doi.org/10.3389/fonc.2021.666826> (2021).
35. Heckl, S. *et al.* The expression of the insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications. *Gastric Cancer* **22**, 1130–1142. <https://doi.org/10.1007/s10120-019-00964-6> (2019).
36. Vizoso, F. *et al.* Pepsinogen C: a possible biological marker of epithelial differentiation in Barrett's esophagus. *Int. J. Biol. Mark.* **16**, 142–145. <https://doi.org/10.1177/172460080101600210> (2001).
37. Hui, D. H. F., Tam, K. J., Jiao, I. Z. F. & Ong, C. J. Semaphorin 3C as a therapeutic target in prostate and other cancers. *Int. J. Mol. Sci.* **20**, 1. <https://doi.org/10.3390/ijms20030774> (2019).
38. Hao, J. & Yu, J. Semaphorin 3C and its receptors in cancer and cancer stem-like cells. *Biomedicines* **6**, 1. <https://doi.org/10.3390/biomedicines6020042> (2018).
39. Hrckulak, D., Kolar, M., Strnad, H. & Korinek, V. TCF/LEF transcription factors: An update from the internet resources. *Cancers* **8**, 1. <https://doi.org/10.3390/cancers8070070> (2016).
40. Gotzel, K. *et al.* In-depth characterization of the Wnt-signaling/beta-catenin pathway in an in vitro model of Barrett's sequence. *BMC Gastroenterol* **19**, 38. <https://doi.org/10.1186/s12876-019-0957-5> (2019).
41. Gerrard, D. *et al.* Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature. *J. Cell. Biochem.* **120**, 3056–3070. <https://doi.org/10.1002/jcb.27449> (2019).
42. Jing, S. *et al.* Expression of TCF7L2 in glioma and its relationship with clinicopathological characteristics and patient overall survival. *Front Neurol* **12**, 627431. <https://doi.org/10.3389/fneur.2021.627431> (2021).

Acknowledgements

The authors gratefully acknowledge the Gene Expression Omnibus (GEO) database, which made the data available.

Author contributions

L.S.: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis; final approval of manuscript. R.W.G.: study design; critical revision of the manuscript for important intellectual content; study supervision; manuscript writing; final approval of manuscript. Z.C.: study design; critical revision of the manuscript for important intellectual content; study supervision; manuscript writing; final approval of manuscript. R.J.: study design; critical revision of the manuscript for important intellectual content; study supervision; manuscript writing; final approval of manuscript. S.Z.: study design; critical revision of the manuscript for important intellectual content; study supervision; manuscript writing; final approval of manuscript. X.X. (Corresponding Author): study concept and design; drafting of the manuscript; critical revision of the manuscript for important intellectual content; final approval of manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-13200-6>.

Correspondence and requests for materials should be addressed to X.X.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022